7 八月 2020 | 01:00:50
Tune in to the second in our 2020 webinar series on decisions in the US and Europe impacting biologics and biosimilars.
Many of the top-selling drugs worldwide are biologics and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, companies continue to face a great deal of uncertainty due to unresolved legal questions involving the governing statutes and patent rights.
Session 2 of this series focuses on recent key decisions, including: